Rollan A, Gonzalez R, Carvajal S, Chianale J
Department of Gastroenterology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago.
J Clin Gastroenterol. 1995 Apr;20(3):189-91. doi: 10.1097/00004836-199504000-00004.
Three patients with achalasia were treated with endoscopic injection of botulinum toxin (BoTx). BoTx (80 U) was injected via a sclerotherapy needle into the lower esophageal sphincter (LES). One patient complained of transient heartburn that resolved after omeprazole treatment. Two patients reported sustained symptomatic improvement. They were able to eat normally 48 h after treatment and have remained symptom free for 5 and 6.5 months, respectively. In these patients, esophageal manometry 4 months after treatment showed a marked reduction of resting LES pressure and the appearance of a previously absent LES relaxation after swallowing. The third patient had only a transient clinical improvement, with occasional dysphagia beginning 3 months after treatment. All patients showed unchanged aperistalsis of the esophageal body. Its less invasive nature compared with other therapeutic alternatives may give BoTX injection a role in the treatment of some patients with achalasia.
三名贲门失弛缓症患者接受了内镜下肉毒杆菌毒素(BoTx)注射治疗。通过硬化治疗针将80单位的BoTx注入食管下括约肌(LES)。一名患者抱怨有短暂的烧心症状,在接受奥美拉唑治疗后症状缓解。两名患者报告症状持续改善。他们在治疗后48小时能够正常进食,分别在5个月和6.5个月内一直没有症状。在这些患者中,治疗后4个月的食管测压显示静息LES压力显著降低,吞咽后出现了之前不存在的LES松弛。第三名患者只有短暂的临床改善,治疗3个月后开始偶尔出现吞咽困难。所有患者食管体部的蠕动均无变化。与其他治疗方法相比,其侵入性较小,这可能使BoTX注射在一些贲门失弛缓症患者的治疗中发挥作用。